株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

痛覚過敏症:パイプライン分析

Hyperalgesia - Pipeline Review, H2 2017

発行 Global Markets Direct 商品コード 293882
出版日 ページ情報 英文 31 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.40円で換算しております。
Back to Top
痛覚過敏症:パイプライン分析 Hyperalgesia - Pipeline Review, H2 2017
出版日: 2017年07月11日 ページ情報: 英文 31 Pages
概要

痛覚過敏症は疼痛反応の増大です。素因には長期間のオピオイド利用、炎症、侵害受容体の損傷、末梢神経の損傷および精神的疾患などが含まれます。治療には抗うつ薬および非ステロイド系抗炎症薬が用いられます。

当レポートでは、痛覚過敏症に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、および薬剤のプロファイルなどについて、体系的な情報を提供しています。

目次

イントロダクション

痛覚過敏症の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

開発中の治療薬:大学/研究機関別

パイプライン製品の概要

  • 初期段階の製品

開発中の製品:企業別

開発中の製品:大学/研究機関別

治療薬の開発に従事している企業

  • Cara Therapeutics, Inc.
  • 塩野義製薬

治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤のプロファイル

  • AX-007
  • BAM-822
  • CR-701
  • GERPOOI
  • ketoprofen
  • LASSBio-873
  • Recombinant Protein to Activate IL-4 and IL-10 Receptors for Osteoarthritis and CNS
  • Small Molecule to Antagonize P2X3 Receptor for Hyperalgesia

最新パイプライン動向

休止状態のプロジェクト

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC9515IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hyperalgesia - Pipeline Review, H2 2017, provides an overview of the Hyperalgesia (Central Nervous System) pipeline landscape.

Hyperalgesia is an increase in pain response. Predisposing factors include long term opioid usage, inflammation, damage to nociceptors, damage to peripheral nerves and psychological disorders. Treatment includes antidepressants and Non-steroidal anti-inflammatory drugs.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hyperalgesia - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Hyperalgesia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hyperalgesia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Hyperalgesia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Preclinical stages are 5 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 4 molecules, respectively.

Hyperalgesia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hyperalgesia (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Hyperalgesia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hyperalgesia (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hyperalgesia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hyperalgesia (Central Nervous System)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hyperalgesia (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hyperalgesia (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Hyperalgesia - Overview
    • Hyperalgesia - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Hyperalgesia - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Hyperalgesia - Companies Involved in Therapeutics Development
    • Cara Therapeutics Inc
    • Novartis AG
    • Hyperalgesia - Drug Profiles
    • AX-007 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BAM-822 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BI-113823 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CR-701 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GERP-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ICE-3682 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ketoprofen - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LASSBio-873 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize GPR4 for Arthritis, Hyperalgesia and Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Hyperalgesia - Dormant Projects
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Hyperalgesia, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Hyperalgesia - Pipeline by Boehringer Ingelheim GmbH, H2 2017
  • Hyperalgesia - Pipeline by Cara Therapeutics Inc, H2 2017
  • Hyperalgesia - Pipeline by Novartis AG, H2 2017
  • Hyperalgesia - Dormant Projects, H2 2017

List of Figures

  • Number of Products by Top 10 Targets, H2 2017
  • Number of Products by Stage and Top 10 Targets, H2 2017
  • Number of Products by Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
Back to Top